MDLN Stock Analysis: Medline Common Stock | NASDAQ
Medical Instruments & Supplies | NASDAQ, USA | Market Cap: 71.912m USD | 12M Return: 3.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 344M
Rev. Trend: 99.9%
Warnings
Tailwinds
No distinct edge detected
Seasonality 0.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Medline Inc. is a large-cap U.S. healthcare supplies company that manufactures and distributes medical-surgical (med-surg) products to hospitals, surgery centers, physician offices, post-acute facilities, and nursing homes in the U.S. and internationally. The med-surg supplies segment is generally considered defensive, as it serves non-discretionary, recurring demand from healthcare providers.
The company operates through two segments. The Medline Brand segment procures and manufactures products across three categories: surgical solutions (operating room and perioperative products such as drapes, gowns, surgical instruments, and procedure trays), front line care (patient-facing items including wound care, exam gloves, skin care, incontinence products, and infection control supplies), and laboratory and diagnostics (point-of-care testing, analyzers, lab consumables, and vital signs monitors). This vertically integrated manufacturing model distinguishes Medline from pure-play distributors.
The Supply Chain Solutions segment distributes third-party national-brand products and offers logistics and supply chain optimization services-including consulting, outsourced warehouse management, third-party logistics, inventory rationalization, and route planning-to both domestic and international customers.
Medline was founded in 1966 and is headquartered in Northfield, Illinois. The company went public on NASDAQ under the ticker MDLN in December 2025.
- Hospital procedure volumes drive surgical solutions segment revenue
- PPE and exam glove pricing normalizes pressuring front line care margins
- Post-IPO capital allocation prioritizes debt reduction and acquisitions
| Net Income: 964.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 0.05 > 1.0 |
| NWC/Revenue: 29.66% < 20% (prev 25.86%; Δ 3.80% < -1%) |
| CFO/TA 0.04 > 3% & CFO 1.52b > Net Income 964.0m |
| Net Debt (10.5b) to EBITDA (2.73b): 3.83 < 3 |
| Current Ratio: 4.41 > 1.5 & < 3 |
| Outstanding Shares: last quarter (825.0m) vs 12m ago 3.15% < -2% |
| Gross Margin: 24.04% > 18% (prev 24.66%; Δ -0.62% > 0.5%) |
| Asset Turnover: 77.25% > 50% (prev 70.02%; Δ 7.23% > 0%) |
| Interest Coverage Ratio: 2.27 > 6 (EBIT TTM 1.80b / Interest Expense TTM 792.0m) |
| A: 0.22 (Total Current Assets 11.2b - Total Current Liabilities 2.54b) / Total Assets 39.0b |
| B: 0.00 (Retained Earnings 122.0m / Total Assets 39.0b) |
| C: 0.05 (EBIT TTM 1.80b / Avg Total Assets 37.7b) |
| D: 0.57 (Book Value of Equity 11.3b / Total Liabilities 19.7b) |
| Altman-Z'' = 2.39 = BBB |
| DSRI: 0.96 (Receivables 3.67b/3.34b, Revenue 29.1b/25.5b) |
| GMI: 1.03 (GM 24.66% / 24.04%) |
| AQI: 0.94 (AQ_t 0.59 / AQ_t-1 0.63) |
| SGI: 1.14 (Revenue 29.1b / 25.5b) |
| TATA: -0.01 (NI 964.0m - CFO 1.52b) / TA 39.0b) |
| Beneish M = -2.97 (Cap -4..+1) = A |
As of July 11, 2026, the stock is trading at USD 41.04 with a total of 3,142,936 shares traded. Over the past week, the price has changed by -4.98%, over one month by +12.32%, over three months by -10.00% and over the past year by +3.90%.
Current recommended Stop Loss: 36.50 (which is 11.1% or 2.8 ATR below the current price).
Medline Common Stock has no consensus analysts rating.
P/E Trailing = 37.7196
P/E Forward = 29.2398
P/S = 2.4678
P/B = 3.24
Revenue TTM = 29.1b USD
EBIT TTM = 1.80b USD
EBITDA TTM = 2.73b USD
Long Term Debt = 12.5b USD (from longTermDebt, last quarter)
Short Term Debt = 142.0m USD (from shortTermDebt, last quarter)
Debt = 12.7b USD (from shortLongTermDebtTotal, last quarter) + Leases 65.0m
Net Debt = 10.5b USD (calculated: Debt 12.7b - CCE 2.24b)
Enterprise Value = 82.4b USD (71.9b + Debt 12.7b - CCE 2.24b)
Interest Coverage Ratio = 2.27 (Ebit TTM 1.80b / Interest Expense TTM 792.0m)
EV/FCF = 54.02x (Enterprise Value 82.4b / FCF TTM 1.52b)
FCF Yield = 1.85% (FCF TTM 1.52b / Enterprise Value 82.4b)
FCF Margin = 5.23% (FCF TTM 1.52b / Revenue TTM 29.1b)
Net Margin = 3.31% (Net Income TTM 964.0m / Revenue TTM 29.1b)
Gross Margin = 24.04% ((Revenue TTM 29.1b - Cost of Revenue TTM 22.1b) / Revenue TTM)
Gross Margin QoQ = 22.65% (prev 24.58%)
Tobins Q-Ratio = 2.11 (Enterprise Value 82.4b / Total Assets 39.0b)
Interest Expense / Debt = 6.24% (Interest Expense 792.0m / Debt 12.7b)
Taxrate = 10.57% (127.0m / 1.20b)
NOPAT = 1.61b (EBIT 1.80b * (1 - 10.57%))
Current Ratio = 4.41 (Total Current Assets 11.2b / Total Current Liabilities 2.54b)
Debt / Equity = 1.13 (Debt 12.7b / totalStockholderEquity, last quarter 11.3b)
Debt / EBITDA = 3.83 (Net Debt 10.5b / EBITDA 2.73b)
Debt / FCF = 6.86 (Net Debt 10.5b / FCF TTM 1.52b)
Total Stockholder Equity = 14.0b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.56% (Net Income 964.0m / Total Assets 39.0b)
RoE = 6.87% (Net Income TTM 964.0m / Total Stockholder Equity 14.0b)
RoCE = 6.78% (EBIT 1.80b / Capital Employed (Equity 14.0b + L.T.Debt 12.5b))
RoIC = 4.57% (NOPAT 1.61b / Invested Capital 35.2b)
WACC = 7.73% (E(71.9b)/V(84.6b) * Re(8.11%) + D(12.7b)/V(84.6b) * Rd(6.24%) * (1-Tc(0.11)))
Discount Rate = 8.11% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 45.36 | Cagr: 2.72%
[DCF] Terminal Value 76.50% ; FCFF base≈1.48b ; Y1≈1.59b ; Y5≈1.93b
[DCF] Fair Price = 22.60 (EV 29.6b - Net Debt 10.5b = Equity 19.1b / Shares 845.6m; r=8.35% [WACC [floored]]; 5y FCF grow 8.54% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 99.91 | Revenue CAGR: 10.63% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.32 | Chg30d=+0.06% | Revisions=+25% | Analysts=22
EPS next Quarter (2026-09-30): EPS=0.39 | Chg30d=-0.03% | Revisions=+50% | Analysts=21
EPS current Year (2026-12-31): EPS=1.51 | Chg30d=-0.17% | Revisions=+0% | GrowthEPS=-15.7% | GrowthRev=+9.3%
EPS next Year (2027-12-31): EPS=1.67 | Chg30d=-0.07% | Revisions=+17% | GrowthEPS=+10.4% | GrowthRev=+12.5%
[Analyst] Revisions Ratio: +42% (up=7, down=2)